Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Beckett

Adult Medicine Williamson, WV Doctor of Osteopathy

NPI 1174575898 CMS profile 189828

184 E 2Nd Ave, Suite 1, Williamson, WV 25661

Open in the dashboard

General payments

$4,858

343 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Beckett of Williamson, WV is reported in the CMS Open Payments database as having received $4,858 across 343 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Adult Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $355 21
2024 General $442 29
2023 General $458 29
2022 General $499 33
2021 General $838 63
2020 General $602 48
2019 General $1,664 120

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Beckett
  • Adult Medicine median
  • Middle half of Adult Medicine
  • National median

In program year 2025, general payments to Christopher Beckett were reported at $355. Among 691 Adult Medicine profiles paid that year, the median was $151 and the middle half received between $51 and $528.

Show as a table
Year Christopher Beckett Adult Medicine median Middle half National median
2019 $1,664 $140 $41–$517 $163
2020 $602 $107 $25–$378 $114
2021 $838 $136 $32–$529 $132
2022 $499 $138 $39–$492 $149
2023 $458 $155 $46–$483 $160
2024 $442 $153 $46–$554 $164
2025 $355 $151 $51–$528 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,006 68 payments
  2. AbbVie, Inc. $589 45 payments
  3. Pfizer Inc. $397 33 payments
  4. AstraZeneca Pharmaceuticals LP $349 24 payments
  5. Janssen Pharmaceuticals, Inc $263 17 payments
  6. Amgen Inc. $225 15 payments
  7. Sanofi-Aventis U.S. LLC $206 18 payments
  8. Abbott Laboratories $197 11 payments
  9. Amarin Pharma Inc. $193 15 payments
  10. Allergan Inc. $172 15 payments
  11. Other $1,261 82 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,852 342 payments
  2. Education $6 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $852 61 payments
  2. RYBELSUS $637 41 payments
  3. UBRELVY $364 24 payments
  4. ELIQUIS $341 29 payments
  5. FARXIGA $309 21 payments
  6. XARELTO $206 16 payments
  7. FreeStyle Libre 2 $197 11 payments
  8. INVOKANA $194 11 payments
  9. ENTRESTO $137 9 payments
  10. Repatha $135 9 payments
  11. Other $3,068 227 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 185 drugs

Part D claims

16,198

Median for Family Practice: 1,826

Drug cost

$1,347,623

Median for Family Practice: $120,094

Branded share of claims

25.2%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 217 $230,013
Mounjaro Tirzepatide Brand 119 $145,009
Eliquis Apixaban Brand 93 $117,200
Januvia Sitagliptin Phosphate Brand 48 $62,617
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 49 $60,977
Jardiance Empagliflozin Brand 52 $54,384
Farxiga Dapagliflozin Propanediol Brand 47 $50,328
Trulicity Dulaglutide Brand 33 $50,115
Xifaxan Rifaximin Brand 15 $47,833
Xarelto Rivaroxaban Brand 43 $44,872

The 10 drugs with the highest cost, of 185 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Records

343 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adult Medicine in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record